<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302584</url>
  </required_header>
  <id_info>
    <org_study_id>FWA //000017585</org_study_id>
    <nct_id>NCT04302584</nct_id>
  </id_info>
  <brief_title>Norepinephrine / Vasopressin Combination for Resuscitation in Septic Shock</brief_title>
  <official_title>Comparison of Between Norepinephrine Alone Versus Norepinephrine / Vasopressin Combination for Resuscitation in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although norepinephrine is commonly used and is the recommended agent for the treatment of
      hypotension in volume-resuscitated hyperdynamic septic shock, Low doses of vasopressin may be
      added to norepinephrine to maintain arterial blood pressure in refractory septic shock and to
      decrease exposure to norepinephrine. The aim of the work is to compare the effect of
      norepinephrine alone and Norepinephrine/vasopressin combination on hemodynamics and tissue
      perfusion in septic shock patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study which was performed on 90 adult of either sex in intensive care unit who developed
      septic shock.45 patients in each group according to the drugs used, by the single blind
      technique as the treating physician only is aware of the drugs used.

      Group 1: patients received IV Norepinephrine infusion starting with (0.1mcg/kg/min).

      Group 2: patients received IV Norepinephrine infusion (Starting with (0.1 mcg/kg/min).
      +Vasopressin infusion at the rate of (0.03 unit/min).

      A comparison was done between both groups as regard:Hemodynamics,Tissue perfusion, C-Reactive
      Protein (mg/L) ,WBC, UREA (mg/dL),CREATININE (mg/dl), NGAL (Neutrophil gelatinase associated
      Lipocalin) (ng/ml). Comparison was done at baseline, then every 6 hours for 48 h as regard
      hemodynamics and tissue perfusion, and at base line then, 24 h and 48 h as regard sepsis
      biomarkers and renal biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">January 6, 2019</completion_date>
  <primary_completion_date type="Actual">January 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lactate Level&amp;SVo2 • (central venous oxygen saturation)SVO2</measure>
    <time_frame>48 hours</time_frame>
    <description>the effect of norepinephrine alone and Norepinephrine/vasopressin combination on tissue perfusion in septic shock patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NGAL, Creat, CRP</measure>
    <time_frame>48 hours</time_frame>
    <description>he effect of norepinephrine alone and Norepinephrine/vasopressin combination in septic shock patients on kidney function and CRP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Septic Shock</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>NE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received IV Norepinephrine infusion starting with (0.1mcg/kg/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NE/VP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received IV Norepinephrine infusion (Starting with (0.1 mcg/kg/min). +Vasopressin infusion at the rate of (0.03 unit/min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>norepinephrine / Vasopressin</intervention_name>
    <description>• The drug infusion was prepared as 100 IU of AVP (Pressyn; Ferring Inc., Toronto, Ontario, Canada) in 250 ml D5W, infused at the rate of 4.5 ml/h for 0.03 IU/min and 15 mg of Norepinephrine (Arterenol; Sanofi-Aventis, Frankfurt, Germany) in 250 ml D5W infused at the rate of 10 ml/h for 10 mcg/min using infusion pump.</description>
    <arm_group_label>NE</arm_group_label>
    <arm_group_label>NE/VP</arm_group_label>
    <other_name>norepinephrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years of both sexes

          -  APACHE Score ≤25

        Exclusion Criteria

          -  Patients with renal impairment (Creatinine&gt;2mg/dl)

          -  Sever Heart Disease (ischemic/valvular)

          -  Peripheral vascular disease (e.g. Raynaud's phenomenon)

          -  Hypersensitivity to Norepinephrine or vasopressin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hanaa El Gendy</name>
      <address>
        <city>Cairo</city>
        <state>Ain Shams University Specialized Hospital</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>March 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Hanaa Mohamed Abdallah ElGendy MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

